Article
Engineered T cells directed at tumors with defined allelic loss.
Molecular immunology - 1 Dec 2020
Hamburger Agnes E, DiAndreth Breanna, Cui Jiajia, Daris Mark E, Munguia Melanie L, Deshmukh Kiran, Mock Jee-Young, Asuelime Grace E, Lim Emily D, Kreke Michelle R, Tokatlian Talar, Kamb Alexander
Abstract excerpt
We describe an approach to cancer therapy based on exploitation of common losses of genetic material in tumor cells (loss of heterozygosity) (Basilion et al., 1999; Beroukhim et al., 2010). This therapeutic concept addresses the fundamental problem of discrimination between tumor and normal cells and can be applied in principle to the large majority of tumors. It utilizes modular activator/blocker elements that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.